BioSpace News Archive

Matthew Kissner to take on executive role in Company

Funds Advancement of Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Technology

Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products.

The traditional 3.5 fl. oz. size will now be increased to 3.9 fl. oz. at no extra charge to the customer.

Suicide is the tenth leading cause of death in the United States, and it is the eleventh leading cause of death in Virginia.

Heritage Pharma Labs Inc. announced that they have acquired a portfolio of 23 abbreviated new drug applications, covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA).

The ExoView™ platform from NanoView Biosciences, Inc., was recognized with the New Product Award at the SLAS2019 International Conference & Exhibition, the annual meeting of the Society for Laboratory Automation and Screening.

The U.S. Food and Drug Administration today approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.

A federal jury in Indianapolis has found an intravenous filter made by Cook Medical Inc. to be defective and dangerous, awarding $3 million to a Georgia woman who suffered medical complications after the filter deteriorated inside her body.

Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving more than 27 million members nationally, released the following statement from Mike Kolar, its senior vice president and general counsel, in response to the Health and Human Services (HHS) Office of Inspector General’s new safe harbor rule proposal to eliminate prescription drug rebates in Medicare Part D: